AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

MESOBLAST LTD

2.340

-0.020-0.85%

Volume:2.39M

Turnover:5.55M

Market Cap:3.03B

PE:-37.68

High:2.350

Open:2.320

Low:2.280

Close:2.360

52wk High:3.310

52wk Low:1.880

Shares:1.30B

Float Shares:786.49M

Volume Ratio:0.77

T/O Rate:0.30%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.062

EPS(LYR):-0.062

ROE:-9.86%

ROA:-4.11%

PB:3.82

PE(LYR):-37.68

Loading ...

Overview Company News Filings

Is Mesoblast's New Clinical Leader Quietly Reframing Its Commercialization Story for Cell Therapies (ASX:MSB)?

Simply Wall St.

A Look At Mesoblast’s (ASX:MSB) Valuation As Leadership Changes Highlight Clinical Growth Plans

Simply Wall St.

Mesoblast appoints Teresa Montagut as Head of Clinical Development and Medical Affairs

DR. Teresa Montagut Appointed as Clinical Development and Medical Affairs Head at Mesoblast

THOMSON REUTERS

Mesoblast Ltd-Appointment of Clinical Development and Medical Affairs Head

THOMSON REUTERS

Cynata Therapeutics' Drug Candidate's Potential Reinforced by Mesoblast Results, Says Euroz Hartleys

MT Newswires Live

Monero price flips daily structure bullish, $473 target emerges

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://au1.tigermoments.com/stock/MSB.AU/news?page=10"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"MSB.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"MSB.AU\",,,,,undefined,":{"symbol":"MSB.AU","market":"AU","secType":"STK","nameCN":"MESOBLAST LTD","latestPrice":2.34,"timestamp":1788243120000,"preClose":2.36,"halted":0,"volume":2391767,"delay":0,"changeRate":-0.00847457627118645,"nameEN":"MESOBLAST LTD","floatShares":786490638,"shares":1296862776,"eps":-0.06210537211468792,"marketStatus":"Closed","change":-0.02,"latestTime":"09-01 16:12:00 AEST","open":2.32,"high":2.35,"low":2.28,"amount":5546577,"amplitude":0.029661,"askPrice":2.35,"askSize":6521,"bidPrice":2.33,"bidSize":2319,"shortable":3,"etf":0,"ttmEps":-0.06210537211468792,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1788307200000},"marketStatusCode":5,"adr":0,"exchange":"ASX","adjPreClose":2.36,"openAndCloseTimeList":[[1788220800000,1788242400000]],"volumeRatio":0.774417,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"MSB.AU","preClose":2.36,"auctionPrice":2.34,"auctionVolume":330705,"auctionTime":1788243005735,"referencePrice":2.34,"referenceTime":1788258603092,"auction":3,"marketStatus":"盘后竞价","timestamp":1788243005735}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"MSB.AU\",,,,,undefined,":{"symbol":"MSB.AU","floatShares":786490638,"roa":"-4.11%","roe":"-9.86%","lyrEps":-0.062109,"volumeRatio":0.774417,"shares":1296862776,"dividePrice":0,"high":2.35,"amplitude":0.029661,"preClose":2.36,"low":2.28,"week52Low":1.88,"pbRate":"3.82","psRate":"18.04","week52High":3.31,"institutionHeld":0,"latestPrice":2.34,"committee":-0.475339,"eps":-0.0621094553252563,"divideRate":0,"volume":2391767,"delay":0,"ttmEps":-0.0621094553252563,"open":2.32,"prevYearClose":2.72,"prevWeekClose":2.46,"prevMonthClose":2.36,"prevQuarterClose":1.955,"fiveDayClose":2.35,"twentyDayClose":2.08,"sixtyDayClose":2.04,"dividendGrowthYears":0,"fiveYearAvgDividendRate":0},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/MSB.AU\",params:#limit:5,,,undefined,":[{"date":"2026-08-26","symbol":"MSB.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1787702400000,"name":null,"time":"","dateTimestamp":1787666400000,"actualEps":null},{"date":"2025-02-26","symbol":"MSB.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1740524400000,"name":null,"time":"","dateTimestamp":1740488400000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"MSB.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"MSB.AU\",pageSize:20,pageCount:10,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2619412639","title":"Is Mesoblast's New Clinical Leader Quietly Reframing Its Commercialization Story for Cell Therapies (ASX:MSB)?","url":"https://stock-news.laohu8.com/highlight/detail?id=2619412639","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619412639?lang=en_us&edition=fundamental","pubTime":"2026-03-14 15:37","pubTimestamp":1773473852,"startTime":"0","endTime":"0","summary":"Earlier this week, Mesoblast Limited created a new senior leadership role and appointed Teresa Montagut MD, PhD as Head of Clinical Development and Medical Affairs, reporting to Chief Medical Officer Dr. Eric Rose, to lead medical affairs, clinical collaborations and investigator-initiated trials across its cell therapy programs.\nBy bringing in a physician-scientist with extensive experience in early pipeline studies and investigator-sponsored research at major biopharmaceutical companies,...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/is-mesoblasts-new-clinical-leader-quietly-reframing-its-comm","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/is-mesoblasts-new-clinical-leader-quietly-reframing-its-comm","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["MSB.AU","MSB","BK7067","BK7501","BK7508","BK4006"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618130978","title":"A Look At Mesoblast’s (ASX:MSB) Valuation As Leadership Changes Highlight Clinical Growth Plans","url":"https://stock-news.laohu8.com/highlight/detail?id=2618130978","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618130978?lang=en_us&edition=fundamental","pubTime":"2026-03-12 21:27","pubTimestamp":1773322071,"startTime":"0","endTime":"0","summary":"Mesoblast (ASX:MSB) has drawn fresh attention after appointing Teresa Montagut MD, PhD as Head of Clinical Development and Medical Affairs, a move that coincides with its upcoming Bell Potter Healthcare Horizons Summit presentation.\nSee our latest analysis for Mesoblast.\nThe recent appointment and upcoming summit appearance come after a tougher stretch for the share price, with a 30 day share price return of 14.4% and a 90 day share price return of 22.74%. However, the 3 year total...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/a-look-at-mesoblasts-asxmsb-valuation-as-leadership-changes","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-msb/mesoblast-shares/news/a-look-at-mesoblasts-asxmsb-valuation-as-leadership-changes","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["MSB.AU","BK4006","MSB","BK7501","BK7508","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618797413","title":"Mesoblast appoints Teresa Montagut as Head of Clinical Development and Medical Affairs","url":"https://stock-news.laohu8.com/highlight/detail?id=2618797413","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618797413?lang=en_us&edition=fundamental","pubTime":"2026-03-12 07:21","pubTimestamp":1773271313,"startTime":"0","endTime":"0","summary":"Mesoblast appointed Teresa Montagut as Head of Clinical Development and Medical Affairs, reporting to Chief Medical Officer Eric Rose. Montagut will lead the medical affairs organization and support investigator-initiated trials and clinical collaborations. She joined Mesoblast from Regeneron, where she was Global Head of Early Pipeline Studies in Oncology and Head of Medical Affairs for Investigator Sponsored Studies in gastrointestinal and genitourinary areas. Mesoblast said Montagut will support efforts to expand indications for its cell therapy programs in pediatric and adult inflammatory conditions.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260311:nNDLbkSytc:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1917777945.USD","LU2210150020.SGD","LU2468319806.SGD","MSB.AU","LU2237438978.USD","LU2023250504.SGD","BK4139","REGN","LU0114720955.EUR","SG9999014039.USD","LU0823416689.USD","BK4585","LU2210149790.SGD","BK4112","LU2362541273.HKD","LU0109394709.USD","LU2362540622.SGD","LU0823434740.USD","LU0058720904.USD","BK7501","LU2106854487.HKD","SG9999014005.SGD","IE00B3QW5Z07.USD","IE00BGHQF748.EUR","LU0053666078.USD","LU2362541513.USD","LU0289739699.SGD","NDAQ","SG9999014013.SGD","BK4588","LU0889565916.HKD","IE00BKPKM429.USD","BK7508","LU2095319765.USD","SG9999014021.USD","LU1974910355.USD","LU0314104364.USD","BK7067","IE00B64PRP62.GBP","LU2089984988.USD","LU0882574055.USD","LU0320765992.SGD","LU0823434583.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618974134","title":"DR. Teresa Montagut Appointed as Clinical Development and Medical Affairs Head at Mesoblast","url":"https://stock-news.laohu8.com/highlight/detail?id=2618974134","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618974134?lang=en_us&edition=fundamental","pubTime":"2026-03-12 07:21","pubTimestamp":1773271299,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260311:nTUA281YNM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7501","BK7508","BK7067","MSB.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618882974","title":"Mesoblast Ltd-Appointment of Clinical Development and Medical Affairs Head","url":"https://stock-news.laohu8.com/highlight/detail?id=2618882974","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618882974?lang=en_us&edition=fundamental","pubTime":"2026-03-12 06:58","pubTimestamp":1773269921,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260311:nTUE4PZNBN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7501","BK7067","BK7508","MSB.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618617137","title":"Cynata Therapeutics' Drug Candidate's Potential Reinforced by Mesoblast Results, Says Euroz Hartleys","url":"https://stock-news.laohu8.com/highlight/detail?id=2618617137","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618617137?lang=en_us&edition=fundamental","pubTime":"2026-03-09 14:37","pubTimestamp":1773038279,"startTime":"0","endTime":"0","summary":"Cynata Therapeutics'  acute graft-versus-host disease  drug candidate, CYP-001's potential has been reinforced by Mesoblast's  fiscal first half results, said Euroz Hartleys in a Monday note.Mesoblast's results showed its product, Ryoncil, which is a mesenchymal stem cell therapy approved by the US FDA for the treatment of paediatric , generated $49 million in net sales during the period and guided towards full-year net sales of $110 million to 120 million.CYP-001 is currently in a phase 2 trial, with topline results expected in June, the note added.The research firm believes that CYP-001 could attract significant commercial interest if it successfully replicates its Phase 1 results, which showed about 86% overall response rate at Day 28 versus about 62% for standard of care.Euroz Hartleys has maintained a speculative buy rating on Cynata Therapeutics with a price target of AU$0.90.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CYP.AU","BK4139","MSB.AU","BK4539","LENZ","BK7508","BK4007","BK7067","BK7501","MESO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617578255","title":"Monero price flips daily structure bullish, $473 target emerges","url":"https://stock-news.laohu8.com/highlight/detail?id=2617578255","media":"cryptonews","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617578255?lang=en_us&edition=fundamental","pubTime":"2026-03-06 03:20","pubTimestamp":1772738431,"startTime":"0","endTime":"0","summary":"Monero price has confirmed a bullish market structure shift on the daily timeframe after reclaiming key support. If the $357 level continues to hold, the next major upside target sits at the $473 resistance.Bullish structure confirmed:Monero printed a higher low followed by a new higher high on the daily chart.$357 flipped to support:Former resistance now acting as key support for continuation.$473 target:Next major high-timeframe resistance if bullish momentum holds.Monero  price is beginning to show renewed bullish momentum after a decisive structural shift on the daily chart. The recent price action suggests that buyers have regained control of the market following a confirmed break in market structure.Such structural confirmations often precede strong directional moves as market participants reposition in line with the new trend. In the broader market narrative, several leading cryptocurrencies attracting trader attention include BCH, XMR, HYPE, and BlockDAG, as investors continue ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"crypto_news_highlight","url":"https://crypto.news/monero-price-flips-daily-structure-473-target-emerges/","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://crypto.news/monero-price-flips-daily-structure-473-target-emerges/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"crypto_news_highlight","symbols":["BK7067","BK7501","MSB.AU","MSB","BK7508","BK4006"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":10,"totalSize":187,"code":"91000000","status":"200"}]}}